Outlook Therapeutics Resubmits BLA for ONS-5010/LYTENAVA™ to FDA with 60-Day Review

summarizeSummary

Outlook Therapeutics has resubmitted its BLA for ONS-5010/LYTENAVA™ to the FDA following a successful appeal, with a decision expected within 60 days, marking a crucial milestone for the financially distressed company.

check_boxKey Events

• BLA Resubmission to FDA

  Outlook Therapeutics announced the resubmission of its Biologics License Application (BLA) for ONS-5010/LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD).

• Follows Successful FDA Appeal

  This resubmission comes after the company successfully appealed a December 2026 Complete Response Letter (CRL) related to the BLA.

• No Additional Trials Required

  The FDA Office of New Drugs concluded that substantial evidence of effectiveness has been established, eliminating the need for additional clinical trials.

• 60-Day PDUFA Review Period

  The resubmission is designated as a Class 1 review, with a PDUFA date and decision expected within 60 days of the FDA's receipt.

auto_awesomeAnalysis

This resubmission of the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ is a critical step for Outlook Therapeutics, especially given its previous going concern warning and Nasdaq delisting risk. The successful appeal of the prior Complete Response Letter (CRL) and the FDA's conclusion that no additional trials are required significantly de-risks the approval pathway. The Class 1 resubmission designation means a decision is expected within 60 days, providing a near-term catalyst that could fundamentally alter the company's financial viability and market position.